Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies

Autor: Caroline Protin, Fanny Gallais, Ben Allal, Sandra De Barros, Fabienne Thomas, Anne Quillet-Mary, Melanie White-Koning, Etienne Chatelut, Lucie Oberic, Loïc Dupré, Fabien Despas, Loïc Ysebaert

Publikováno v: Clinical Pharmacokinetics
Clinical Pharmacokinetics, 2020, 59 (9), pp.1171-1183. ⟨10.1007/s40262-020-00884-0⟩
Clinical Pharmacokinetics, Springer Verlag, 2020, 59 (9), pp.1171-1183. ⟨10.1007/s40262-020-00884-0⟩

Ibrutinib is used for the treatment of chronic lymphocytic leukemia and other lymphoid malignancies. The aim of this work is to develop a population pharmacokinetic model for ibrutinib and its dihydrodiol metabolite to quantify pharmacokinetic inter-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18466632280bd56f9f163b49b4fa5076
https://hal.science/hal-02989879/document